The "SUFU Gene Basal Cell Nevus Syndrome Genetic Test" is a specialized diagnostic procedure offered by DNA Labs UAE, aimed at identifying mutations in the SUFU gene, which are associated with Basal Cell Nevus Syndrome (BCNS). BCNS, also known as Gorlin Syndrome, is a rare genetic condition characterized by the development of multiple basal cell carcinomas, jaw cysts, and various other abnormalities. The SUFU gene plays a crucial role in the Hedgehog signaling pathway, which is important for cell growth and division; mutations in this gene can disrupt normal cell behavior, leading to the manifestations of BCNS.
This genetic test involves analyzing the patient's DNA, extracted from a blood sample, to look for specific mutations in the SUFU gene that are linked to the syndrome. It is a powerful tool for early diagnosis, allowing for timely intervention and management of the condition. The test is particularly recommended for individuals with a family history of BCNS or those showing symptoms suggestive of the syndrome.
At DNA Labs UAE, the cost of the SUFU Gene Basal Cell Nevus Syndrome Genetic Test is set at 4400 AED. The test is conducted under strict quality controls and with the expertise of skilled geneticists, ensuring accurate and reliable results. By opting for this test, patients and their families can gain valuable insights into their genetic health, guiding them in making informed decisions about their medical care and lifestyle.
The PTCH2 Gene Basal Cell Nevus Syndrome Due to Germline PTCH2 Mutation Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the PTCH2 gene, which are associated with Basal Cell Nevus Syndrome (BCNS). This condition, also known as Gorlin Syndrome, is an inherited disorder characterized by the development of multiple basal cell carcinomas, jaw cysts, skeletal abnormalities, and other systemic manifestations. The test, priced at 4400 AED, involves analyzing the patient's DNA to detect any genetic alterations in the PTCH2 gene, enabling early diagnosis and the opportunity for targeted management strategies. By identifying individuals carrying the germline PTCH2 mutation, healthcare providers can offer personalized monitoring and treatment plans to mitigate the risk of complications associated with BCNS. This genetic test represents a crucial step in the proactive management of patients at risk for or diagnosed with Basal Cell Nevus Syndrome, offering a path towards improved outcomes through precision medicine.
The "CCDC8 Gene Three M Syndrome Type 3 Genetic Test" is a specialized diagnostic assessment available at DNA Labs UAE, designed to identify mutations in the CCDC8 gene, which are linked to Three M Syndrome Type 3. This rare genetic disorder is characterized by growth retardation, distinctive facial features, and skeletal abnormalities. The test plays a crucial role in confirming a diagnosis, thereby facilitating early intervention and management strategies for affected individuals. Priced at 4400 AED, this genetic test provides valuable insights into the CCDC8 gene's status, enabling healthcare professionals to tailor treatment and support to the specific needs of patients and their families.
The FAM58A Gene Toe Syndactyly Telecanthus and Anogenital and Renal Malformations Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to detect mutations in the FAM58A gene. These mutations are known to be associated with a rare genetic disorder characterized by a combination of physical anomalies. Key features of the condition include syndactyly (fusion of the toes), telecanthus (an increased distance between the inner corners of the eyes), and various anogenital and renal malformations. The test is crucial for individuals showing symptoms of these conditions, as it can provide a definitive diagnosis, guiding treatment options and management plans for affected individuals and their families. The cost of the test is 4400 AED, reflecting the specialized nature of the genetic analysis and the comprehensive information it provides to patients and healthcare providers.
The MSX1 Gene Tooth Agenesis Selective Type 1 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the MSX1 gene, which are associated with selective tooth agenesis type 1. This condition is characterized by the congenital absence of one or more teeth, excluding the third molars or wisdom teeth, and can significantly impact oral health and aesthetics. The test involves analyzing the patient's DNA to detect any genetic alterations in the MSX1 gene that might lead to this specific type of tooth agenesis.
The process is crucial for individuals exhibiting symptoms of the condition or those with a family history of tooth agenesis, as it helps in confirming the diagnosis, understanding the risk of transmission to offspring, and guiding treatment and management strategies. Conducted in the state-of-the-art facilities of DNA Labs UAE, the test ensures accuracy, confidentiality, and comprehensive genetic counseling.
The cost of the MSX1 Gene Tooth Agenesis Selective Type 1 Genetic Test is set at 4400 AED, reflecting the intricate technology and expertise involved in conducting this genetic analysis. This investment not only provides valuable insights into the genetic underpinnings of tooth agenesis but also empowers patients and their families with crucial information for making informed health decisions.
The "PAX9 Gene Tooth Agenesis Selective Type 3 Genetic Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the PAX9 gene, which are known to cause Selective Tooth Agenesis Type 3. This condition is characterized by the congenital absence of one or more teeth, excluding the third molars, due to genetic anomalies. The PAX9 gene plays a crucial role in the early development of teeth, and mutations in this gene can lead to various dental anomalies, including missing teeth.
The test is performed through a simple and non-invasive process, where a sample of the patient's DNA is collected, typically through a saliva swab or a blood sample. This sample is then analyzed in the laboratory using advanced genetic sequencing technologies to detect any mutations in the PAX9 gene that could lead to tooth agenesis.
The cost of the PAX9 Gene Tooth Agenesis Selective Type 3 Genetic Test at DNA Labs UAE is set at 4400 AED. This price includes the cost of the sample collection, the genetic analysis, and a comprehensive report that details the findings of the test. This report can be a valuable tool for dental professionals and genetic counselors in devising a personalized care plan for individuals affected by this condition, potentially including dental prosthetics or orthodontic treatments to address the missing teeth and improve oral health and aesthetics.
Overall, this genetic test is a crucial step for individuals experiencing selective tooth agenesis, as it provides a definitive diagnosis of the condition, enabling targeted and effective treatment plans.
The SALL1 Gene Townes-Brocks Syndrome Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the SALL1 gene, which are associated with Townes-Brocks syndrome (TBS). TBS is a rare genetic condition that affects various parts of the body, including the ears, thumbs, and anus, and can also impact the kidneys and heart. Symptoms and severity can vary widely among individuals.
The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to detect the presence of mutations in the SALL1 gene. This gene plays a crucial role in the development of structures in the embryo, and mutations can lead to the development of Townes-Brocks syndrome.
Offered at a cost of 4400 AED, this genetic test is a valuable tool for families seeking a diagnosis for symptoms consistent with TBS, for individuals with a family history of the condition, or for couples considering starting a family and wanting to understand their genetic risks. Early diagnosis through the SALL1 Gene Townes-Brocks Syndrome Genetic Test can provide crucial information for managing the condition, including guiding treatment decisions and connecting families with appropriate support and resources.
The GDF1 Gene Transposition of Great Arteries Dextro-Looped 3 Genetic Test is a specialized diagnostic assessment available at DNA Labs UAE. This test is designed to identify mutations in the GDF1 gene, which have been associated with congenital heart defects, specifically the transposition of the great arteries (d-TGA). d-TGA is a serious and rare heart condition present at birth, where the two main arteries carrying blood out of the heart are switched in position, leading to poor oxygenation of blood.
Given the critical nature of diagnosing and managing d-TGA, the GDF1 genetic test is an essential tool for clinicians. It aids in confirming the diagnosis, understanding the genetic underpinnings of the condition, and guiding treatment plans. Furthermore, it can be instrumental in family planning and genetic counseling for families affected by d-TGA.
The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing services. The cost of the GDF1 Gene Transposition of Great Arteries Dextro-Looped 3 Genetic Test is 4400 AED. This investment covers the comprehensive analysis required to detect any mutations in the GDF1 gene that could lead to or indicate a susceptibility to d-TGA. Through this test, DNA Labs UAE provides a crucial service for patients and families seeking clarity on this congenital heart condition, contributing significantly to the field of genetic diagnostics and cardiovascular health.
The "MED13L Gene Transposition of the Great Arteries Dextro-Looped 1 Genetic Test" is a specialized diagnostic examination aimed at identifying mutations in the MED13L gene, which have been associated with congenital heart defects, particularly Transposition of the Great Arteries (d-TGA). This condition is characterized by an abnormal arrangement of the two main arteries leaving the heart, leading to insufficient oxygenation of blood throughout the body. The test plays a crucial role in early detection and management of the condition, providing essential information for healthcare providers to devise appropriate treatment plans.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test employs advanced genetic sequencing techniques to accurately analyze the MED13L gene for any abnormalities that may contribute to the development of d-TGA. With a cost of 4400 AED, the test represents a significant investment in the health and well-being of individuals at risk of or suspected to have this congenital heart defect. Through early and precise diagnosis, affected families can access targeted interventions and counseling, potentially improving outcomes and quality of life for those impacted by this condition.
The TCOF1 gene test for Treacher Collins Syndrome Type 1 is a specialized genetic analysis designed to detect mutations in the TCOF1 gene, which is closely associated with Treacher Collins Syndrome (TCS). TCS is a genetic disorder characterized by distinctive facial anomalies and deformities of the ears, eyes, cheekbones, and chin. This condition is inherited in an autosomal dominant pattern, meaning a mutation in just one of the two copies of the gene can cause the disorder.
Conducted at DNA Labs UAE, this genetic test is crucial for early diagnosis, which can significantly aid in the management and treatment planning for affected individuals. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the TCOF1 gene.
The cost of the TCOF1 gene test for Treacher Collins Syndrome Type 1 at DNA Labs UAE is 4400 AED. This cost covers the comprehensive analysis required to identify the genetic mutation responsible for the syndrome. Early diagnosis through this test can provide families with valuable information regarding the course of the syndrome, potential treatments, and the risk of passing the condition on to future generations.
